Corbion NV (CRBN) AI Stock Analysis

• Market Cap: €977.00M
• Dividend Yield: 3.76%
• Average Volume (3M): 102.30K
• Price to Earnings (P/E): 14.4
• Beta (1Y): 1.32
• Revenue Growth: -3.45%
• EPS Growth: -5.55%
• Country: NL
• Employees: 2,383
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Chemicals - Specialty
• EPS (TTM): 0.73
• Shares Outstanding: 58,250,310
• 10 Day Avg. Volume: 105,536
• 30 Day Avg. Volume: 102,296
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €21.63
• Price Target Upside: 28.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 68 Neutral
• Price Target: €18.50 ▲(9.60% Upside)

Corbion NV's overall stock score is driven by its strong valuation and improved financial performance. The stock's technical indicators suggest caution, as it trades below key moving averages. The absence of earnings call data and corporate events limits additional insights.

Corbion NV Business Overview & Revenue Model

Company Description

Corbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. The company offers ingredient solutions made from renewable resources for the food, home and personal care, pharmaceutical, animal nutrition, medical device, and bioplastics markets. It markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes Money

Corbion NV generates revenue through multiple key streams, primarily from the sale of ingredients and solutions to the food and biochemicals industries. The company’s food segment includes products such as emulsifiers, preservation agents, and functional ingredients that improve food safety and quality, while its biochemicals segment focuses on lactic acid and its derivatives used in various applications, including bioplastics and pharmaceuticals. Significant partnerships with food manufacturers and companies in the bioplastics industry further enhance its market reach and revenue potential. Additionally, Corbion's commitment to sustainability and innovation allows it to tap into growing consumer trends favoring eco-friendly and health-conscious products, bolstering its earnings through premium pricing and increased demand.

Corbion NV Financial Statement Overview

Summary

Corbion NV demonstrates a strong financial performance with notable profitability improvements despite a revenue decline. The balance sheet is stable but has moderate leverage, with high debt levels potentially posing a risk. Cash flow generation is improving, though conversion from net income is moderate. Overall, the company shows resilience and effective management with some areas requiring attention.

Income Statement

Corbion NV shows a mixed performance in its income statement. The gross profit margin for the latest year is approximately 24.2%, indicating a strong ability to convert revenue into gross profit. However, the net profit margin has improved significantly to approximately 14.9% from the previous year's 5.0%, driven by increased net income. The revenue growth rate shows a decline of 10.8% from the previous year, suggesting challenges in maintaining top-line growth. The EBIT and EBITDA margins are 6.0% and 13.4% respectively, reflecting efficient operational management despite the revenue decline.

Balance Sheet

The balance sheet presents a stable but leveraged financial position. The debt-to-equity ratio is approximately 0.66, indicating moderate leverage. The return on equity stands high at 24.9%, showcasing effective use of shareholders' capital to generate earnings. The equity ratio is 50%, pointing to a well-balanced asset financing structure through equity and liabilities. However, the high debt levels pose a potential risk in a fluctuating market environment.

Cash Flow

The cash flow statement highlights some concerns. The free cash flow growth has been positive, with an increase from €16.1 million to €99.9 million, indicating improved cash generation capability. However, the operating cash flow to net income ratio of 0.96 suggests less cash generation relative to net income, potentially due to working capital needs or other operational factors. The free cash flow to net income ratio stands at 0.52, showing moderate conversion of net income into free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29B	1.44B	1.46B	1.07B	986.50M
Gross Profit	312.10M	352.70M	324.30M	265.80M	269.80M
EBITDA	172.00M	198.00M	194.00M	133.10M	154.90M
Net Income	192.20M	72.90M	90.00M	78.30M	73.10M
Balance Sheet
Total Assets	1.55B	1.70B	1.72B	1.36B	1.09B
Cash, Cash Equivalents and Short-Term Investments	49.30M	70.20M	58.20M	42.20M	51.60M
Total Debt	509.20M	785.50M	759.20M	503.20M	335.80M
Total Liabilities	773.80M	1.06B	1.10B	806.50M	578.20M
Stockholders Equity	772.50M	636.20M	625.70M	554.10M	516.00M
Cash Flow
Free Cash Flow	99.90M	16.10M	-182.60M	-122.00M	24.50M
Operating Cash Flow	184.10M	165.40M	53.20M	26.70M	113.40M
Investing Cash Flow	166.00M	-146.80M	-213.30M	-123.70M	-81.30M
Financing Cash Flow	-371.70M	-5.30M	173.90M	85.90M	-23.90M

Corbion NV Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 16.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:CRBN, the sentiment is Negative. The current price of 16.88 is below the 20-day moving average (MA) of 17.28, below the 50-day MA of 17.34, and below the 200-day MA of 19.27, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 42.54 is Neutral, neither overbought nor oversold. The STOCH value of 3.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:CRBN.

Corbion NV Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBN	68 Neutral	€977.00M	14.40	8.84%	3.76%	-3.45%	-5.55%
AKZA	65 Neutral	10.46B	25.06	9.95%	3.24%	-1.57%	-29.52%
FFARM	64 Neutral	377.55M	7.31	9.56%	4.73%	8.76%	195.20%
IMCD	63 Neutral	5.38B	20.01	12.57%	2.36%	6.09%	-7.18%
OCI	53 Neutral	1.01B	-4.95	222.01%	59.31%	0.00%	0.00%
AVTX	44 Neutral	170.59M	-4.00	-28.03%	―	-12.31%	23.77%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%